Medical cannabis authorization linked to reduced opioid use in high-dose patients
Among chronic opioid users in Alberta, medical cannabis authorization was associated with reduced opioid dosing, particularly in those on the highest doses.
Quick Facts
What This Study Found
Patients on high-dose opioids (OME > 100) who received medical cannabis authorization showed a significant decrease in opioid use of 435.5 mg OME over six months compared to matched controls.
Key Numbers
5,373 matched pairs; average age 52 years, 54% female; high-dose patients (OME > 100) saw a decrease of 435.5 mg OME (95% CI: -596.8 to -274.2) over 6 months
How They Did This
Researchers propensity-score matched 5,373 medical cannabis-authorized chronic opioid users with non-authorized controls in Alberta from 2013 to 2018. They used interrupted time series analysis to track weekly average oral morphine equivalents 26 weeks before and 52 weeks after authorization.
Why This Research Matters
With opioid overdose deaths continuing to climb in North America, any intervention that meaningfully reduces opioid dosing in high-risk patients deserves attention. This population-level data from a Canadian province offers real-world evidence beyond clinical trials.
The Bigger Picture
This adds to a growing body of evidence suggesting cannabis may function as an opioid-sparing agent, though the effect appears most pronounced in patients already on dangerously high opioid doses.
What This Study Doesn't Tell Us
Short follow-up period of one year. Cannabis authorization does not confirm actual use. Effects were modest in low-dose opioid users. Observational design limits causal conclusions.
Questions This Raises
- ?Do these opioid reductions persist beyond one year?
- ?What happens to pain management outcomes when opioids are reduced?
- ?Which cannabis products or dosing patterns drive the strongest opioid-sparing effect?
Trust & Context
- Key Stat:
- 435.5 mg OME reduction in high-dose opioid patients over 6 months
- Evidence Grade:
- Large population-level cohort with propensity-score matching and interrupted time series analysis across a Canadian province.
- Study Age:
- Published in 2021 using data from 2013-2018.
- Original Title:
- Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.
- Published In:
- BMC public health, 21(1), 843 (2021)
- Authors:
- Lee, Cerina(7), Lin, Mu, Martins, Karen J B, Dyck, Jason R B, Klarenbach, Scott, Richer, Lawrence, Jess, Ed, Hanlon, John G, Hyshka, Elaine, Eurich, Dean T
- Database ID:
- RTHC-03282
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Did medical cannabis completely replace opioids?
Not in most cases. The study found intermediate effects on opioid use overall, with the most meaningful reductions in patients who started on the highest doses.
How large was this study?
It included 5,373 medical cannabis patients matched to an equal number of controls, all chronic opioid users in Alberta.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBD-oil-quality-guide
- CBT-cannabis-recovery
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cannabis-relapse-cycle-pattern
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- cold-turkey-vs-taper-quit-weed
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-quit-weed
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- medical-benefits-of-cannabis
- meditation-mindfulness-weed-withdrawal
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-before-surgery
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- seniors-older-adults-cannabis-risks-medications
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-breastfeeding-THC-breast-milk
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-03282APA
Lee, Cerina; Lin, Mu; Martins, Karen J B; Dyck, Jason R B; Klarenbach, Scott; Richer, Lawrence; Jess, Ed; Hanlon, John G; Hyshka, Elaine; Eurich, Dean T. (2021). Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.. BMC public health, 21(1), 843. https://doi.org/10.1186/s12889-021-10867-w
MLA
Lee, Cerina, et al. "Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.." BMC public health, 2021. https://doi.org/10.1186/s12889-021-10867-w
RethinkTHC
RethinkTHC Research Database. "Opioid use in medical cannabis authorization adult patients ..." RTHC-03282. Retrieved from https://rethinkthc.com/research/lee-2021-opioid-use-in-medical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.